A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
F CappuzzoL Crinò

Abstract

Gemcitabine is one of the most active drugs against non-small-cell lung cancer (NSCLC). Preclinical data suggested that gemcitabine efficacy could be improved by increasing the dose or by increasing the infusion duration. This study has been designed in order to explore two different approaches of gemcitabine dose intensification in patients with advanced NSCLC. A total of 121 chemonaive patients with locally advanced or metastatic NSCLC not suitable for a platinum-based chemotherapy were randomly allocated to chemotherapy with gemcitabine 1500 mg/m2 on days 1 and 8 every 3 weeks by standard 30 min intravenous infusion (arm A), or gemcitabine 10 mg/m2/min for 150 min on days 1 and 8 every 3 weeks by intravenous infusion at fixed dose rate (arm B). One hundred and seventeen patients were fully analyzed. No difference in response rate (16.1% versus 9.9%, p=0.28), median time to disease progression (4 months versus 4.5 months, p=0.34) median survival (9.8 months in both arms), and 1-year survival (42.6% versus 39.0% p=0.98) was detected in arms A and B, respectively. No treatment-related deaths occurred. Main hematological toxicities were grade 3-4 neutropenia observed in 17.9% of patients in group A and in 49.2% of individuals in...Continue Reading

References

Jan 1, 1981·Cancer·A B MillerA Winkler
Feb 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·U GatzemeierM Voi
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Nov 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G V ScagliottiUNKNOWN Italian Lung Cancer Project
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Margaret TemperoJames Abbruzzese
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe GiacconeDavid H Johnson
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstDavid H Johnson
Dec 18, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·T Le ChevalierJ H Schiller
Feb 17, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S BakaN Thatcher
May 5, 2005·Journal of the National Cancer Institute·Federico CappuzzoMarileila Varella-Garcia
Jul 27, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstUNKNOWN TRIBUTE Investigator Group

❮ Previous
Next ❯

Citations

Jan 1, 2009·OncoTargets and Therapy·Luca Toschi, Federico Cappuzzo
Oct 31, 2012·Indian Journal of Cancer·M Zwitter
Jun 1, 2007·Expert Review of Pharmacoeconomics & Outcomes Research·Luca ToschiFederico Cappuzzo
Jun 24, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Matjaz ZwitterVesna Zadnik
Nov 15, 2011·Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria·A Ramón-LópezB Valenzuela
Aug 7, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Cesare GridelliUNKNOWN MILES Investigators
May 20, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·M FrühG D'Addario
Jul 27, 2007·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Mark N KirsteinRobert A Kratzke
Nov 21, 2007·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Jian Ping XiongWang Yong Gong
Mar 3, 2009·Critical Reviews in Oncology/hematology·Adolfo FavarettoCesare Gridelli
Dec 28, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·C TibaldiA Falcone
Dec 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter GrimisonMatthew J Links
Dec 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Varsha Gandhi
Oct 17, 2020·Clinical Pharmacokinetics·Ellen J B Derissen, Jos H Beijnen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.